SEC Form SC 13G/A filed by Vericel Corporation (Amendment)
$VCEL
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/9/2024 | $57.00 | Buy | Canaccord Genuity |
| 6/20/2024 | $55.00 | Buy | TD Cowen |
| 1/25/2024 | $39.00 → $51.00 | Hold → Buy | Truist |
| 8/8/2023 | $39.00 | Neutral → Buy | BTIG Research |
| 11/10/2022 | Buy → Neutral | BTIG Research | |
| 11/9/2022 | Buy → Hold | Truist | |
| 10/14/2022 | $40.00 | Overweight | Stephens |
| 2/25/2022 | $40.00 → $45.00 | Outperform | SVB Leerink |
Canaccord Genuity initiated coverage of Vericel with a rating of Buy and set a new price target of $57.00
TD Cowen initiated coverage of Vericel with a rating of Buy and set a new price target of $55.00
Truist upgraded Vericel from Hold to Buy and set a new price target of $51.00 from $39.00 previously
10-Q - Vericel Corp (0000887359) (Filer)
8-K - Vericel Corp (0000887359) (Filer)
SCHEDULE 13G/A - Vericel Corp (0000887359) (Subject)
Total Revenue Growth of 20% to $63.2 Million, with MACI Revenue Growth of 21% to $53.5 Million Gross Margin Increased More than 400 Basis Points to 74% Adjusted EBITDA Growth of 112% to $13.4 Million, with Adjusted EBITDA Margin Increase of More than 900 Basis Points to 21% Approximately 600 MACI Arthro Surgeons Trained to Date Received FDA IND Clearance for Phase 3 MACI Ankle Clinical Study Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the second quarte
CAMBRIDGE, Mass., July 17, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report its second-quarter 2025 financial results on Thursday, July 31, 2025. Vericel's management will host a conference call and webcast at 8:30 a.m. ET to discuss its financial results and business highlights. The live webcast can be accessed on the Investor Relations section of the Vericel website at http://investors.vcel.com/events-presentations. Presentation slides for the conference call will be available on the webcast and on the website. A replay of the webcast will be avail
CAMBRIDGE, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will participate in a fireside chat at the Truist Securities MedTech Conference at 9:20 a.m. ET on Tuesday, June 17 2025. A webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com. About Vericel Corporation Vericel is a leading provider of advanced therapies for the sports medicine and severe burn care markets. The Company combines innovations in biology with medical technologies, resulting in a hi
4 - Vericel Corp (0000887359) (Issuer)
4 - Vericel Corp (0000887359) (Issuer)
4 - Vericel Corp (0000887359) (Issuer)
CAMBRIDGE, Mass., July 22, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the appointment of Karen Mahoney as Chief Human Resources Officer following the retirement of Heidi Hassen, who served as Vericel's Head of Human Resources since September 2010. Ms. Mahoney joins Vericel with more than 20 years of experience across the life sciences and medical device sectors, most recently serving as Chief Human Resources Officer at Abiomed, a global medical device company that was acquired by Johnson & Johnson in December 2022. At Abiomed, Ms. Mahoney led all aspects of HR strategy and
Hagen, Former Chief Technical Officer of Sonoma Biotherapeutics, Joins as A-Alpha's First Independent Board Member SEATTLE, June 27, 2023 /PRNewswire-PRWeb/ -- A-Alpha Bio, a synthetic biology and machine learning company that measures and engineers protein-protein interactions, announced the appointment of Heidi Hagen to their Board of Directors. Hagen will be A-Alpha Bio's first independent board member. Hagen has been a leader in the Biotechnology industry for 30 years. Over the course of her career, she has built an extensive track record in leading strategy and operations to progress innovative technologies from ideation to commercialization. Having been a core member of pharma companie
New Independent Board Chair, Dr. Paul K. Wotton, brings 35 years of experience building private and public biopharmaceutical companies with significant business development expertise. Kytopen, an MIT-spin out and biotechnology company leading advancements in novel high-throughput cellular and genome engineering platforms, today announced the appointment of Paul K. Wotton, Ph.D. to Chair the Kytopen Board of Directors. Following the appointment of Dr. Wotton, the Board will comprise of five directors including Ann DeWitt, Adam Wieschhaus, Cullen Buie, and Paulo Garcia. Dr. Paul Wotton received his Ph.D. in Pharmaceutical Sciences from the University of Nottingham and is an experienced CEO,
Total Revenue Growth of 20% to $63.2 Million, with MACI Revenue Growth of 21% to $53.5 Million Gross Margin Increased More than 400 Basis Points to 74% Adjusted EBITDA Growth of 112% to $13.4 Million, with Adjusted EBITDA Margin Increase of More than 900 Basis Points to 21% Approximately 600 MACI Arthro Surgeons Trained to Date Received FDA IND Clearance for Phase 3 MACI Ankle Clinical Study Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the second quarte
CAMBRIDGE, Mass., July 17, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report its second-quarter 2025 financial results on Thursday, July 31, 2025. Vericel's management will host a conference call and webcast at 8:30 a.m. ET to discuss its financial results and business highlights. The live webcast can be accessed on the Investor Relations section of the Vericel website at http://investors.vcel.com/events-presentations. Presentation slides for the conference call will be available on the webcast and on the website. A replay of the webcast will be avail
Record First Quarter MACI Revenue of $46.3 Million and First Quarter Total Revenue of $52.6 Million Approximately 400 MACI Arthro Surgeons Trained to Date, with Year-to-Date Biopsy Growth Over 30% for Trained Surgeons Second Quarter Total Revenue and MACI Revenue Growth Expected to be in the Low- to Mid-20% Range Full-Year 2025 Revenue Guidance Reaffirmed and Profitability Guidance Raised Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business hi
SC 13G/A - Vericel Corp (0000887359) (Subject)
SC 13G/A - Vericel Corp (0000887359) (Subject)
SC 13G/A - Vericel Corp (0000887359) (Subject)